Last update 21 Nov 2024

Dulanermin(Shanghai Gebaide Biotechnology Co., Ltd.)

Overview

Basic Info

Drug Type
Tumor necrosis factors
Synonyms-
Target
TRAIL receptor
Mechanism
TRAIL receptor agonists, Apoptosis stimulants
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication-
Inactive Indication
Advanced Lung Non-Small Cell Carcinoma
Originator Organization
Shanghai Gebaide Biotechnology Co., Ltd.
Active Organization-
Inactive Organization
Shanghai Gebaide Biotechnology Co., Ltd.
Drug Highest PhasePendingPhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Dulanermin(Shanghai Gebaide Biotechnology Co., Ltd.)
CTR20161061 / Not yet recruitingPhase 3
注射用重组人凋亡素2配体治疗晚期非小细胞肺癌随机、双盲、安慰剂平行对照、多中心Ⅲ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of recombinant human apoptosis-inducing factor 2 ligand for the treatment of advanced non-small cell lung cancer
NCT03083743 / Unknown statusPhase 3
A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection（Dulanermin for Injection）in the Treatment of Advanced Non-small Cell Lung Cancer
100 Clinical Results associated with Dulanermin(Shanghai Gebaide Biotechnology Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Dulanermin(Shanghai Gebaide Biotechnology Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Dulanermin(Shanghai Gebaide Biotechnology Co., Ltd.)
Login to view more data
100 Deals associated with Dulanermin(Shanghai Gebaide Biotechnology Co., Ltd.)
Login to view more data

External Link

KEGGWikiATCDrug Bank
D09395--
DB12349

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
Shanghai Gebaide Biotechnology Co., Ltd.
01 Oct 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03083743 (Pubmed)
ManualManual
Phase 3
Non-Small Cell Lung Cancer
452
vinorelbine+cisplatin+dulanermin
(duklojjrpt) = auhgrgmqen ixyohchbfm (flhrjaeged )
View more
Positive
01 Apr 2018
vinorelbine+cisplatin+Placebo
(duklojjrpt) = cfbipluwus ixyohchbfm (flhrjaeged )
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free